Tetrous Bolsters its EnFix Product Lineup With U.S. Patent

Tetrous Inc. has been issued a fourth U.S. patent for the EnFix family of demineralized cortical bone fiber implants and its manufacturing method.  
 
The EnFix allograft product family is designed to enhance healing at the tendon to bone interface—i.e., at the enthesis, where failure often occurs. The demineralized bone fiber (DBF) implants provide osteoinductivity and osteoconductivity, while FormLok technology imparts shape retention to the device, even in arthroscopic surgery’s wet environment, according to the company. Optimal biologic performance is provided in an implant that has minimal disruption to the current surgical technique.
 
The newly issued patent, “Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair,” further augments Tetrous’ intellectual property portfolio covering demineralized cortical bone fiber implants, bone healing, and enhancement of tendon to bone repair.  “We are pleased the U.S. Patent Office has again recognized the uniqueness of our technology and has granted this additional patent,” stated Andy Carter, Ph.D., Tetrous co-founder, director, and co-inventor on the issued patent. “Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in the enthesis repair market.”
 
Tetrous claims more than 700 EnFix RC and EnFix TAC implants have been implanted in the United States and Australia since July 1, 2023. Follow-up magnetic resonance imaging on patients at six months post-surgery are consistently showing enthesis reformation, tendon thickening, and little to no edema. While the majority of the procedures have been for rotator cuff, the company is expanding the technology to additional applications in hip, biceps, achilles, and ACL procedures. 
 
Founded in 2019, Tetrous uses next-generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. Its core technology has been used in over 150,000 implants in spine applications. Tetrous enjoys significant IP protection for its EnFix family of products with multiple issued patents and, additionally, has an exclusive license to the demineralized bone fiber technology used in its products for sports medicine applications from TheraCell, an ISTO Biologics company.